Current Science

Open Access Open Access  Restricted Access Subscription Access

Role of Inflammation in Diabetic Retinopathy:Therapeutic Targets


Affiliations
1 Department of Surgery/Ophthalmology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States
2 Department of Cell Biology and Physiology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States
 

Inflammation plays a key role in the pathogenesis of diabetic retinopathy (DR), leading to alterations in the blood–retinal barrier and increased vascular permeability. Many anti-VEGF medications are now available for the treatment of DR, but response to these medications is not as robust in patients with diabetic macular oedema. Newer biologic agents are currently under study to improve the treatment of DR. These have shown promising results to both decrease the treatment burden of intravitreal injections and improve visual outcomes for diabetic patients.

Keywords

Chemokines, Cytokines, Diabetic Retinopathy, Drug Therapy, Inflammation.
User
Notifications
Font Size


  • Role of Inflammation in Diabetic Retinopathy:Therapeutic Targets

Abstract Views: 575  |  PDF Views: 146

Authors

Samuel Hobbs
Department of Surgery/Ophthalmology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States
Finny Monickaraj
Department of Surgery/Ophthalmology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States
Paul McGuire
Department of Cell Biology and Physiology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States
Arup Das
Department of Surgery/Ophthalmology, University of New Mexico School of Medicine, MSC 10 8000, 1600 University Blvd. NE, Albuquerque, NM 87131, United States

Abstract


Inflammation plays a key role in the pathogenesis of diabetic retinopathy (DR), leading to alterations in the blood–retinal barrier and increased vascular permeability. Many anti-VEGF medications are now available for the treatment of DR, but response to these medications is not as robust in patients with diabetic macular oedema. Newer biologic agents are currently under study to improve the treatment of DR. These have shown promising results to both decrease the treatment burden of intravitreal injections and improve visual outcomes for diabetic patients.

Keywords


Chemokines, Cytokines, Diabetic Retinopathy, Drug Therapy, Inflammation.

References





DOI: https://doi.org/10.18520/cs%2Fv113%2Fi07%2F1287-1295